You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Ariad halts US sales of key drug

The outlook for Ariad Pharmaceuticals Inc. went from bad to worse Thursday after the troubled maker of cancer drugs bowed to regulatory pressure to stop marketing its leukemia treatment in the United States, casting a shadow over the company’s future.

Ariad said the move came in response to a request by the Food and Drug Administration, which on Thursday issued a drug safety communication warning that the company’s pill, called Iclusig, carried “the risk of life-threatening blood clots and severe narrowing of blood vessels.”

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week